Fundación Weber

What Fundación Weber does

Fundación Weber is a Spain-registered private non-profit foundation (CIF G-87.880.803) that operates as a specialized health-economics and pharmacoeconomics consulting firm with more than 20 years of consolidated market presence. Its service offering covers five interrelated domains — regulatory affairs, pharmacoeconomics, health economics, market access, and marketing — and is delivered through project-based engagements for pharmaceutical laboratories, biotech firms, rare-disease patient organizations, and healthcare-system policy makers. Service fees are negotiated per project and are not publicly disclosed.

The foundation's operational footprint spans four country offices — Madrid (Spanish headquarters), Lisbon (Lusophone markets), Mexico City (Latin American markets), and Dover, Delaware (United States) — and is structured around a core foundation entity plus two operational spin-offs: Weber Data & Technology (data and technology solutions) and Weber Strategic Foresight (strategic foresight consulting). Supporting sub-brands include Aula Virtual (online training), newsRARE (a rare-disease news platform), and OFWISE (a health-economics initiative). The organization publishes an extensive bilingual portfolio of articles, conference communications, reports, infographics, books, and journals, and maintains active presence at industry events such as Infarma 2026 and the IV AELMHU National Conference on Advanced Therapies for Rare Diseases (May 2026).

The revenue model is project-based consulting under non-profit status, with no disclosed revenue, headcount, or external investment. Documented commercial relationships include named co-development partnerships with Amgen (SROI-EOT 2025 on Thyroid Eye Disease), Sanofi (Conexión PTI 360 on immune thrombocytopenia), Servier (2026 socioeconomic burden report on IDH-mutant grade 2 glioma), and AELMHU. The foundation has no proprietary technology platform described in the input, and its core "technology" is methodological expertise in pharmacoeconomic evaluation, cost-effectiveness analysis, and SROI-style social value quantification validated by multidisciplinary expert committees.

Name

Fundación Weber

Legal name

Fundación Weber

Website

https://weber.org.es

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Fundación Weber is a Spain-based non-profit foundation that provides specialized consulting in pharmacoeconomics, health economics, regulatory affairs, market access, and marketing to pharmaceutical, biotech, and healthcare organizations across Europe, Latin America, and the United States.

Ownership category

akta.pro rank

Product category

Healthcare Economics Consulting

NAICS

Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Financial Management & Performance Improvement Consulting (BPAHACAF)

akta.pro secondary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Health economics consulting
• Pharmacoeconomic evaluation
• Market access consulting
• Regulatory affairs consulting
• Rare disease research

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Distribution channels1 record

Marketing channels4 records

Core offering

Fundación Weber provides specialized consulting services that generate value through innovative and technological solutions across regulatory affairs, pharmacoeconomics, health economics, market access, and marketing. Its engagements include socioeconomic burden studies, cost-effectiveness analyses, health technology assessments, SROI quantification, and disease-burden research for pharmaceutical, biotech, healthcare, and patient-advocacy clients, with more than 20 years of consolidated market experience.

Product overview

Fundación Weber is a specialized consulting firm with over 20 years of experience providing innovative and technological solutions in regulatory, pharmacoeconomic, health economics, market access, and marketing. The organization operates through its core foundation entity and two spin-offs: Weber Data & Technology (focused on data and technology solutions) and Weber Strategic Foresight (focused on strategic foresight). Its offerings include a portfolio of specialized publications and research reports such as the glioma IDH mutation socioeconomic burden report, the Conexión PTI 360 report on immune thrombocytopenia, and the Proyecto SROI-EOT report on thyroid eye disease. The Foundation also supports initiatives including newsRARE (focused on rare diseases) and OFWISE. The company maintains a presence across Spain, Portugal, Mexico, and the United States.

Differentiator

Problem solved

Functional benefit

Brands

• Weber Data & Technology: Spin-off focused on data and technology services
• Weber Strategic Foresight
• Aula Virtual
• newsRARE

Products and services

• Health Economics and Pharmacoeconomics Consulting Specialized consulting delivering economic evaluations of pharmacological treatments, cost-effectiveness analyses, and health technology assessments for pharmaceutical, biotech, and healthcare clients.
• Regulatory Affairs Consulting Specialized regulatory consulting supporting pharmaceutical and biotech clients with evidence generation and compliance for product approval and market entry.
• Market Access Consulting Strategic consulting on market access for pharmaceutical and biotech products, including value demonstration, reimbursement strategy, and stakeholder engagement support.
• Socioeconomic Burden Studies and SROI Methodology Project-based consulting engagements quantifying socioeconomic burden, productivity losses, and social return on investment (SROI) for specific diseases such as Thyroid Eye Disease, IDH-mutant glioma, and primary immune thrombocytopenia in Spain.
• Weber Data & Technology A Weber spin-off offering data and technology solutions that leverage the parent foundation's expertise in health economics and pharmacoeconomics.
• Weber Strategic Foresight A Weber spin-off providing analytical and forward-looking strategic foresight consulting services in the health economics and regulatory space.

Quantifiable outcome

• SROI ratio of 4.7:1 for active phase and 3.4:1 for inactive phase of Thyroid Eye Disease when improving care approaches are implemented (from Amgen-Weber SROI-EOT 2025 project)

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• ServiercoreStrategic or Co-development PartnerCollaboration between Servier and Fundación Weber to develop comprehensive reports on the socioeconomic burden of diseases. Specifically, the partnership produced a 2026 report quantifying productivity losses of patients and caregivers affected by IDH-mutant grade 2 glioma in Spain, using a social cost model based on scientific evidence and validated by a multidisciplinary expert committee.
• AmgencoreStrategic or Co-development PartnerPartnership with Amgen to develop the SROI-EOT 2025 (Social Return on Investment - Eye Orthopedic Thyroid Disease) project, which estimated the social value of improving care for Thyroid Eye Disease in Spain. The project applied SROI methodology to identify unmet needs and improvement proposals based on training, early diagnosis, care coordination, and multidisciplinary follow-up with digital tool support.
• SanoficoreStrategic or Co-development PartnerCollaboration with Sanofi on the Conexión PTI 360 project (Connection PTI 360: 15 Challenges, a Plan for Primary Immune Thrombocytopenia), which identified the main unmet needs of Primary Immune Thrombocytopenia (PTI) in Spain and developed improvement recommendations through a holistic perspective. The project involved a multidisciplinary working group of healthcare professionals, healthcare managers, and patients.
• AELMHU (Asociación Española de Laboratorios de Medicamentos de Uso Humano)coreStrategic or Co-development PartnerAELMHU organized its IV National Conference on Advanced Therapies for Rare Diseases in Madrid on May 6, 2026, where Weber participated as a key stakeholder. Experts, clinicians, researchers, patients, and authorities coincided that advanced therapies for rare diseases require a comprehensive approach beyond the healthcare scope.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Adelphi Values: Specialized HEOR and patient-centered outcomes consultancy focused on value communication, evidence generation, and market access for pharmaceutical and biotech clients. Directly comparable to Weber's health economics and value demonstration practice, particularly in rare disease and specialty therapy areas.
• Putnam Associates: Pharmaceutical and biotech strategy consulting firm specializing in market access, pricing, and HEOR evidence. Directly comparable to Weber's market access and health economics service lines for pharmaceutical and biotech clients.
• Evidera (PPD/Thermo Fisher): Specialized HEOR, market access, and real-world evidence consulting firm serving pharmaceutical and biotech clients globally. Directly comparable to Weber's core pharmacoeconomics and health economics practice, though Evidera operates at substantially larger scale with broader therapeutic and geographic reach.
• Lumanity: Specialized pharma/biotech consulting firm formed from the merger of several HEOR and market access firms (including Cello Health, BresMed, and others). Closely comparable to Weber on HEOR, value demonstration, and market access services for pharmaceutical sponsors.
• Pharmerit (OPEN Health Group): Specialized health economics and outcomes research (HEOR) consultancy now part of OPEN Health. Closely comparable to Weber in service portfolio (pharmacoeconomic modeling, market access, burden of disease studies) and customer base (pharma and biotech sponsors).

Broad incumbents

• IQVIA: Largest global provider of clinical, commercial, and HEOR consulting services to pharmaceutical and biotech clients. Comparable as a primary competitor to Weber for health economics, market access, and real-world evidence projects, but operates at vastly greater scale with proprietary technology platforms.
• ICON plc: Global clinical research organization and pharma consulting provider following the PRA Health Sciences merger. Overlaps with Weber on HEOR, market access, and evidence generation services for pharmaceutical sponsors, though serves a much broader geographic and therapeutic footprint.
• Certara: Provider of biosimulation, regulatory science, and market access services to pharmaceutical companies. Comparable to Weber on the pharmacoeconomic modeling and regulatory affairs side, but differentiated by its proprietary software platforms (Phoenix, Simcyp) that Weber lacks.
• Charles River Associates (CRA): Global consulting firm with a Life Sciences practice covering HEOR, market access, and pharma strategy. Comparable to Weber for health economics and life sciences consulting work, though CRA offers a much broader portfolio across multiple industries.

Emerging players

• Wickenstones: Specialized life sciences consulting firm with services in market access, pricing, and commercial strategy. Comparable to Weber in offering pharma-focused strategic consulting with HEOR and market access emphasis, though more commercially oriented rather than foundation-structured.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/fundaci%C3%B3n-weber

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fundación Weber